medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-16-32-38medsovet-2630Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАISHEMIC HEART DISEASEПациент с ишемической болезнью сердца и мультифокальным атеросклерозом как оптимизировать прогноз?A patient with сoronary artery disease and multifocal atherosclerosis. How to optimize the prognosis?БарбарашО. Л.BarbarashO. L.

директор ФГБНУ «НИИ КПССЗ»;

чл.-корр. РАН, д.м.н., профессор, заведующая кафедрой кардиологии и сердечно-сосудистой хирургии

Kemerovo

КашталапВ. В.KashtalapV. V.

д.м.н., заведующий лабораторией патофизиологии мультифокального атеросклероза отдела мультифокального атеросклероза;

доцент кафедры кардиологии и сердечно-сосудистой хирургии 

Kemerovo

ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; ФГБОУ ВО «Кемеровский государственный медицинский университет Минздрава России»РоссияFederal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases; Federal State Budget Educational Institution of Higher Education Kemerovo State Medical University the Ministry of Health of the Russian FederationRussian Federation2018260920180163238Copyright © Барбараш О.Л., Кашталап В.В., 20182018Барбараш О.Л., Кашталап В.В.Barbarash O.L., Kashtalap V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2630

В обзорной статье на основании зарубежных и отечественных исследований, рекомендаций Европейского и Североамериканского кардиологических и хирургических сообществ обобщены позиции экспертов в отношении клиникопрогностической значимости мультифокального атеросклероза у пациентов с разными формами ишемической болезни сердца и влияния этого феномена на общий сердечно-сосудистый риск. Даны позиции современных клинических рекомендаций в отношении антитромботической терапии у пациентов с периферическим атеросклерозом. Представлены перспективные позиции по оптимизации антитромботической терапии на основании недавнего клинического исследования.

The review article summarized the positions of experts on the clinical and prognostic significance of multifocal atherosclerosis in patients with different forms of coronary heart disease and the impact of this phenomenon on overall cardiovascular risk based on the foreign and domestic studies, the guidelines of the European and North American Cardiological and Surgical Associations. It also presents the review of the modern clinical guidelines for antithrombotic therapy in patients with peripheral atherosclerosis. The review presents prospects for the optimization of antithrombotic therapy based on a recent clinical study.

ишемическая болезнь сердцамультифокальный атеросклерозпрогнозантитромботическая терапиясoronary artery diseasemultifocal atherosclerosisprognosisantithrombotic therapyReferencesБарбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные проблемы сердечно-сосудистых заболеваний, 2012, 1: 12-16.Barbarash O.L., Kashtalap V.V. Diagnosis of latent forms of non-coronary atherosclerosis in acute coronary syndrome patients. Is there any practical sense? Complex issues of cardiovascular diseases, 2012, 1: 12-16 (in Russian).Aboyans V, Ricco J-B, Bartelink M-LE L, Bjo¨rck M, Brodmann M, Cohnert T, Collet J-P, Czerny M. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39: 763–821. doi: 10.1093/eurheartj/ehx095.Aboyans V, Ricco J-B, Bartelink M-LE L, Bjo¨rck M, Brodmann M, Cohnert T, Collet J-P, Czerny M. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39: 763–821. doi: 10.1093/eurheartj/ehx095.Безденежных А.В., Сумин А.Н., Иванов С.В., Барбараш О.Л. Предикторы госпитальных осложнений коронарного шунтирования: роль мультифокального атеросклероза. Сибирский медицинский журнал, 2016, 31(1): 35-41.Bezdenezhnikh A.V., Sumin A.N., Ivanov S.V., Barbarash O.L. Predictors of hospital complications after coronary artery bypass grafting: the role of multifocal atherosclerosis. Siberian Medical Journal, 2016, 31(1): 35-41.Бернс С.А., Зыкова Д.С., Зыков М.В., Шмидт Е.А., Юхно Е.С., Нагирняк О.А., Барбараш О.Л. Роль мультифокального атеросклероза в реализации новых сердечно-сосудистых осложнений у пациентов в течение года после перенесенного острого коронарного синдрома без подъема сегмента ST. Кардиология, 2013, 8: 15-23.Berns S.A., Zykova D.S., Zykov M.V., Shmidt E.A., Yukhno E.S., Nagirnyak O.A., Barbarash O.L. The Role of Multifocal Atherosclerosis in Realization of New Cardiovascular Complications during One Year after Non ST-Elevation Acute Coronary Syndrome. Kardiologiia, 2013, 8: 15-23.Барбараш О.Л., Усольцева Е.Н., Кашталап В.В., Коломыцева И.С., Сизова И.Н., Волыкова М.А., Шибанова И.А. Роль субклинического воспаления в прогрессировании мультифокального атеросклероза в течение года после инфаркта миокарда. Кардиология, 2014, 8: 19-25.Barbarash O.L., Usoltseva E.N., Kashtalap V.V., Kolomytseva I.S., Sizova I.N., Volykova M.A., Shibanova I.A. The role of subclinical inflammation in progression of multifocal atherosclerosis during one year after myocardial infarction. Kardiologiia, 2014, 8: 19-25.Безденежных А.В., Сумин А.Н., Казачек Я.В., Осокина А.В., Байракова Ю.В., Кондрикова Н.В., Иванов С.В., Барбараш О.Л. Мультифокальность и прогрессирование некоронарного атеросклероза у пациентов, перенесших коронарное шунтирование. Атеросклероз и дислипидемии, 2016, 3: 95-106.Bezdenezhnykh A.V.,  Sumin A.N.,  Kazachek Y.V.,  Osokina A.V.,  Bayrakova Y.V.,  Kondrikova N.V.,  Ivanov S.V.,  Barbarash O.L. Multifocality and progression of non-coronary atherosclerosis in patients undergoing coronary artery bypass grafting. Journal of Atherosclerosis and Dyslipidemia, 2016, 3: 95-106.Гайфулин Р.А., Сумин А.Н., Иванов С.В., Барбараш Л.С. Анализ отдаленных результатов хирургического лечения больных с мультифокальным атеросклерозом в различных возрастных группах. Атеросклероз и дислипидемии. 2017, 2: 48-57.Gajfulin R.A., Sumin A.N., Ivanov S.V., Barbarash L.S. Analysis of the long-term results of surgical treatment of patients with multifocal atherosclerosis in different age groups. Journal of Atherosclerosis and Dyslipidemia, 2017, 2: 48-57.Гайфулин Р.А., Сумин А.Н., Иванов С.В., Барбараш Л.С. Выживаемость после хирургического лечения больных с мультифокальным атеросклерозом в различных возрастных группах. Комплексные проблемы сердечно-сосудистых заболеваний, 2017, 6(2): 6-18.Gajfulin R.A., Sumin A.N., Ivanov S.V., Barbarash L.S. Survival after surgical treatment of multifocal atherosclerosis. Complex issues of cardiovascular diseases, 2017, 6(2): 6-18.Барбараш Л.С. Двадцатипятилетний итог развития кардиологии Кузбасса. Комплексные проблемы сердечно-сосудистых заболеваний, 2016, 2: 6-13.Barbarash L.S. 25-year summary of the development of Kuzbass cardiology. Complex issues of cardiovascular diseases, 2016, 2: 6-13.Сумин А.Н. Субклинический мультифокальный атеросклероз: как его выявлять и надо ли? Артериальная гипертензия, 2017, 23(1): 69–73. doi: 10.18705/1607-419X-2017-23-1-69-73.Sumin AN. Subclinical multifocal atherosclerosis: should it be detected? Arterial Hypertension, 2017, 23(1): 69–73.Сумин А.Н., Косова М.А., Медведева Ю.Д., Щеглова А.В., Макаров С.А., Артамонова Г.В., Барбараш Л.С. Амбулаторное наблюдение больных атеросклерозом сосудов нижних конечностей с позиции кардиолога. Российский кардиологический журнал, 2016, 12(140): 58–63. http://dx.doi.org/10.15829/1560-4071-2016-12-58-63.Sumin A.N., Kosova М.А., Medvedeva Yu.D., Scheglova А.V., Makarov S.А., Artamonov G.V., Barbarash L.S. Outpatient follow-up of the lower extremities atherosclerosis patients from cardiologist point of view. Russian Journal of Cardiology. 2016, 12(140): 58–63.Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol, 1994, 23: 1091-1095.Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol, 1994, 23: 1091-1095.Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med, 2013, 18: 176-184.Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med, 2013, 18: 176-184.Badheka AO, Rathod AD, Bharadwaj AS, Bhat S, Kizilbash MA, Veeranna V, Pidlaon V, Jacob S, Afonso L. Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease. Angiology, 2011, 62: 473-479.Badheka AO, Rathod AD, Bharadwaj AS, Bhat S, Kizilbash MA, Veeranna V, Pidlaon V, Jacob S, Afonso L. Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease. Angiology, 2011, 62: 473-479.Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. OPUS-TIMI 16 Investigators: Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary SyndromesThrombolysis In Myocardial Infarction (OPUSTIMI) 16 study. Am Heart J, 2003, 145: 622-627.Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. OPUS-TIMI 16 Investigators: Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary SyndromesThrombolysis In Myocardial Infarction (OPUSTIMI) 16 study. Am Heart J, 2003, 145: 622-627.Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, Nissen SE, Nicholls SJ: Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol, 2011, 57: 1220-1225.Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, Nissen SE, Nicholls SJ: Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol, 2011, 57: 1220-1225.Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT. CRUSADE Investigators: Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J, 2009, 30: 1195-1202.Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT. CRUSADE Investigators: Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J, 2009, 30: 1195-1202.Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, Budaj A, Avezum A, Allegrone J, FitzGerald G, Steg PG. GRACE Investigators: Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol, 2007, 100: 1-6.Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, Budaj A, Avezum A, Allegrone J, FitzGerald G, Steg PG. GRACE Investigators: Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol, 2007, 100: 1-6.Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, Patel MR, Ohman EM, Gibler WB, Peterson ED, Roe MT. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes, 2012, 5: 541-549.Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, Patel MR, Ohman EM, Gibler WB, Peterson ED, Roe MT. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes, 2012, 5: 541-549.Jonelid B, Johnston N, Berglund L, Andre ́n B, Kragsterman B, Christersson C. Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction. Eur J Intern Med, 2016, 30: 55-60.Jonelid B, Johnston N, Berglund L, Andre ́n B, Kragsterman B, Christersson C. Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction. Eur J Intern Med, 2016, 30: 55-60.Sutton-Tyrrell K, Rihal C, Sellers MA, Burek K, Trudel J, Roubin G, Brooks MM, Grogan M, Sopko G, Keller N, Jandova ́ R. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Cardiol, 1998, 81: 375-381.Sutton-Tyrrell K, Rihal C, Sellers MA, Burek K, Trudel J, Roubin G, Brooks MM, Grogan M, Sopko G, Keller N, Jandova ́ R. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Cardiol, 1998, 81: 375-381.Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol, 2006, 48: 1567-1572.Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol, 2006, 48: 1567-1572.Singh M, Lennon RJ, Darbar D, Gersh BJ, Holmes DR Jr, Rihal CS. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc, 2004, 79: 1113-1118.Singh M, Lennon RJ, Darbar D, Gersh BJ, Holmes DR Jr, Rihal CS. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc, 2004, 79: 1113-1118.Manfrini O, Ricci B, Cenko E, Dorobantu M, Kalpak O, Kedev S, Kneevic B, Koller A, Milicic D, Vasiljevic Z, Badimon L, Bugiardini R. ISACSTC Investigators: Association between comorbidities and absence of chest pain in acute coronary syndrome with in-hospital outcome. Int J Cardiol, 2016, 217(Suppl): S37-S43.Manfrini O, Ricci B, Cenko E, Dorobantu M, Kalpak O, Kedev S, Kneevic B, Koller A, Milicic D, Vasiljevic Z, Badimon L, Bugiardini R. ISACSTC Investigators: Association between comorbidities and absence of chest pain in acute coronary syndrome with in-hospital outcome. Int J Cardiol, 2016, 217(Suppl): S37-S43.Dencker D, Pedersen F, Engstrøm T, Køber L, Højberg S, Nielsen MB, Schroeder TV, Lnn L. Major femoral vascular access complications after coronary diagnostic and interventional procedures: a Danish register study. Int J Cardiol, 2016, 202: 604-608.Dencker D, Pedersen F, Engstrøm T, Køber L, Højberg S, Nielsen MB, Schroeder TV, Lnn L. Major femoral vascular access complications after coronary diagnostic and interventional procedures: a Danish register study. Int J Cardiol, 2016, 202: 604-608.Chu D, Bakaeen FG, Wang XL, Dao TK, LeMaire SA, Coselli JS, Huh J. The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg, 2008, 86: 1175-1180.Chu D, Bakaeen FG, Wang XL, Dao TK, LeMaire SA, Coselli JS, Huh J. The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg, 2008, 86: 1175-1180.Ferket BS, Spronk S, Colkesen EB, Hunink MG. Systematic review of guidelines on peripheral artery disease screening. Am J Med, 2012, 125: 198-208e3.Ferket BS, Spronk S, Colkesen EB, Hunink MG. Systematic review of guidelines on peripheral artery disease screening. Am J Med, 2012, 125: 198-208e3.Collet JP, Cayla G, Ennezat PV, Leclercq F, Cuisset T, Elhadad S, Henry P, Belle L, Cohen A, Silvain J, Barthelemy O, Beygui F, Diallo A, Vicaut E, Montalescot G. AMERICA Investigators: Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: the randomized AMERICA Study. Int J Cardiol, 2018, 254: 36-42.Collet JP, Cayla G, Ennezat PV, Leclercq F, Cuisset T, Elhadad S, Henry P, Belle L, Cohen A, Silvain J, Barthelemy O, Beygui F, Diallo A, Vicaut E, Montalescot G. AMERICA Investigators: Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: the randomized AMERICA Study. Int J Cardiol, 2018, 254: 36-42.Manfrini O, Amaduzzi PL, Cenko E, Bugiardini R. Prognostic implications of peripheral artery disease in coronary artery disease. Current Opinion in Pharmacology, 2018, 39: 121–128.Manfrini O, Amaduzzi PL, Cenko E, Bugiardini R. Prognostic implications of peripheral artery disease in coronary artery disease. Current Opinion in Pharmacology, 2018, 39: 121–128.Комаров А.Л., Новикова Е.С., Гуськова Е.В., Яровая Е.Б., Самко А.Н., Панченко Е.П. Новые возможности антитромботической терапии больных с периферическим и распространенным атеросклеротическим поражением. Рациональная фармакотерапия в кардиологии, 2018, 14(2): 272-283. doi: 10.20996/1819-6446-2018-14-2-272-283.Komarov A.L., Novikova E.S., Guskova E.V., Yarovaya E.B., Samko A.N., Panchenko E.P. New Possibilities of Antithrom botic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion. Rational Pharmacotherapy in Cardiology, 2018, 14(2): 272-283.Комаров А.Л. Д-димер и функция тромбоцитов как предикторы тромботических осложнений у больных с атеросклеротическим поражением артерий нижних конечностей (результаты 5-летнего наблюдения). Кардиология, 2000, 9: 16-22.Komarov A.L. D-dimer and function of platelets as predictors of thrombotic events in patients with peripheral arterial disease of the lower extremities (results of 5 years’ observation). Kardiologiia, 2000, 9: 16-22.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348(9038): 1329-39. doi: 10.1016/S01406736(96)09457-3.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348(9038): 1329-39. doi: 10.1016/ S01406736(96)09457-3.Hiatt WR, Fowkes F G, Heizer G et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med, 2017, 376(1): 32-40. doi: 10.1056/NEJMoa1611688.Hiatt WR, Fowkes F G, Heizer G et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med, 2017, 376(1): 32-40. doi: 10.1056/NEJMoa1611688.Bosch J, Eikelboom JW, Connolly SJ et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol, 2017, 33(8): 1027-1035. doi: 10.1016/j.cjca.2017.06.001.Bosch J, Eikelboom JW, Connolly SJ et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol, 2017, 33(8): 1027-1035. doi: 10.1016/j.cjca.2017.06.001.Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J, 2018, 199: 83-91. doi: 10.1016/j.ahj.2018.01.011.Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J, 2018, 199: 83-91. doi: 10.1016/j.ahj.2018.01.011.Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2017, 69: 1465–508.Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2017, 69: 1465–508.Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pompo selli FB, et al. Society for Vascular Surgery prac tice guide lines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg, 2015, 61: 2S–41S.Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pompo selli FB, et al. Society for Vascular Surgery prac tice guide lines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg, 2015, 61: 2S–41S.Brass E.P., Hiatt W.R. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. Circulation, 2017, 136: 785–6.Brass E.P., Hiatt W.R. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. Circulation, 2017, 136: 785–6.Hussain MA, Al-Omran M, Creager MA, Anand SS, Verma S, Bhatt DL. Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. J Am Coll Cardiol, 2018, 71(21): 2450-2467. doi: 10.1016/j.jacc.2018.03.483.Hussain MA, Al-Omran M, Creager MA, Anand SS, Verma S, Bhatt DL. Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. J Am Coll Cardiol, 2018, 71(21): 2450-2467. doi: 10.1016/j.jacc.2018.03.483.Barbarash OL, Zykov MV, Pecherina TB, Kashtalap VV, Barbarash LS, Kutikhin AG. The Prognostic Value of Peripheral Artery Diseases in Patients with ST-Segment Elevation Myocardial Infarction. Disease Markers, 2013, 35(6): 877–882. http: //dx.doi.org/10.1155/2013/487807.Barbarash OL, Zykov MV, Pecherina TB, Kashtalap VV, Barbarash LS, Kutikhin AG. The Prognostic Value of Peripheral Artery Diseases in Patients with ST-Segment Elevation Myocardial Infarction. Disease Markers, 2013, 35(6): 877–882. http: //dx.doi.org/10.1155/2013/487807.Jones WS, Patel MR. Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. J Am Coll Cardiol, 2018, 71(3): 352-362. doi: 10.1016/j.jacc.2017.11.021.Jones WS, Patel MR. Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. J Am Coll Cardiol, 2018, 71(3): 352-362. doi: 10.1016/j. jacc.2017.11.021.

The authors declare that there are no conflicts of interest present.